Gritstone Bio Current Ratio 2017-2022 | GRTS

Gritstone Bio current ratio from 2017 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Gritstone Bio Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2022-03-31 $0.19B $0.03B 5.65
2021-12-31 $0.22B $0.04B 5.52
2021-09-30 $0.22B $0.04B 6.01
2021-06-30 $0.18B $0.02B 8.25
2021-03-31 $0.20B $0.02B 9.30
2020-12-31 $0.18B $0.03B 6.50
2020-09-30 $0.07B $0.02B 3.35
2020-06-30 $0.09B $0.02B 4.93
2020-03-31 $0.11B $0.02B 6.09
2019-12-31 $0.13B $0.02B 6.73
2019-09-30 $0.16B $0.02B 6.76
2019-06-30 $0.19B $0.02B 10.22
2019-03-31 $0.14B $0.01B 9.57
2018-12-31 $0.16B $0.02B 10.43
2018-09-30 $0.08B $0.01B 6.13
2018-06-30 $0.00B 0.00
2018-03-31 $0.00B 0.00
2017-12-31 $0.00B 0.00
2017-09-30 $0.00B 0.00
2016-12-31 $0.04B $0.00B 15.39
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.141B $0.048B
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient?s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients? TSNA to drive the patient?s immune system to attack and destroy tumors.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.213B 9.87
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.280B 16.23
Biohaven Pharmaceutical Holding (BHVN) United States $10.017B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.593B 0.00
Emergent Biosolutions (EBS) United States $1.775B 7.60
Arcus Biosciences (RCUS) United States $1.357B 34.40
Myovant Sciences (MYOV) United Kingdom $1.000B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.360B 0.00
Zymeworks (ZYME) Canada $0.346B 0.00
Ambrx Biopharma (AMAM) United States $0.149B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.099B 0.00